Bradley J. Monk US gynecologic oncologist, academician and researcher
Monk, Bradley J.
VIAF ID: 38851960 (Personal)
Permalink: http://viaf.org/viaf/38851960
Preferred Forms
- 100 0 _ ‡a Bradley J. Monk ‡c US gynecologic oncologist, academician and researcher
- 100 1 _ ‡a Monk, Bradley J.
- 100 1 _ ‡a Monk, Bradley J.
- 100 1 _ ‡a Monk, Bradley J.
-
-
4xx's: Alternate Name Forms (2)
5xx's: Related Names (1)
Works
Title | Sources |
---|---|
Myths & facts about cervical cancer : what you need to know | |
Ovarian cancer: relevant therapy, not timing, is paramount | |
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer | |
The pediatrician's role in preventing cervical cancer | |
Pelvic radiation improves local control after hysterectomy for uterine leiomyosarcoma: a 20-year experience | |
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer | |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study | |
Philip John DiSaia, MD: Available Light & The Origin of Storms | |
Photodynamic therapy of high-grade cervical intraepithelial neoplasia with 5-aminolevulinic acid | |
PO004LBA/#1515 Efficacy and safety of avutometinib + defactinib in recurrent low-grade serous ovarian cancer following prior systemic therapy | |
Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma | |
The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study | |
Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndrome | |
Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysis. | |
Progress in record numbers of approved therapies for gynecologic cancers: The lack of upfront approval for newly diagnosed cases | |
Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial | |
The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma | |
Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group Study | |
Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study. | |
Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways | |
Quality-of-life results used to endorse changes in standard of care for recurrent platinum-sensitive ovarian cancer | |
Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy | |
Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study | |
The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. | |
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice | |
Reducing the burden of glandular carcinomas of the uterine cervix | |
Relationship between social support, quality of life, and Th2 cytokines in a biobehavioral cancer survivorship trial | |
Reply to F.M. Muggia | |
Reply to Farolfi et al and Haines et al | |
Reply to W.A.A. Tjalma and J.S. Grossman | |
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study | |
The role of antioxidants and vitamin A in ovarian cancer: results from the Women's Health Initiative | |
Safety and efficacy of salvage nano-particle albumin bound paclitaxel in recurrent cervical cancer: a feasibility study | |
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer | |
Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance | |
SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm | |
Simultaneous characterization of somatic events and HPV-18 integration in a metastatic cervical carcinoma patient using DNA and RNA sequencing. | |
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma. | |
The spectrum and clinical sequelae of human papillomavirus infection | |
State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer | |
Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial [corrected]. | |
Supportive care for women with gynecologic cancers | |
Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer | |
Systemic therapy for recurrent endometrial cancer: a review of North American trials | |
Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm | |
Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001. | |
Topotecan in the management of cervical cancer | |
Trabectedin as a chemotherapy option for patients with BRCA deficiency | |
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer | |
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis | |
Treatment of metastatic cervical cancer: future directions involving targeted agents | |
Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiation | |
Updates on drug discovery in ovarian cancer | |
Vaccines against human papillomavirus and cervical cancer: promises and challenges | |
The vaginal and gastrointestinal microbiomes in gynecologic cancers: a review of applications in etiology, symptoms and treatment. | |
Validation of PROMIS emotional distress short form scales for cervical cancer | |
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer | |
What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer? | |
What is the standard therapy for bulky stage IB cervical cancer? | |
When is being in a hurry going too fast? Lessons learned from clinical trials in cervical cancer | |
Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials | |
Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers? | |
Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America? |